Dandekar Atul sold $207K of MAZE
Dandekar Atul (CSBO) sold 7,500 shares of Maze Therapeutics, Inc. (MAZE) at $27.58 ($0.21M total) on 2026-08-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is routine and unlikely to affect the stock price.
Market read
Low relevance; typical insider sale with minimal market impact.
What to watch
Potential upcoming clinical data could make the insider's remaining position more relevant.
Background
Form 4 filing reports an insider's open‑market sale under a 10b5‑1 plan.
Ticker impact
Officer Dandekar Atul sold 7,500 shares for $206,824 via a 10b5‑1 plan, reducing his stake to 26,250 shares.
No significant impact expected.
The sale size (~$0.2M) is small relative to market cap and follows a pre‑arranged plan.
Market effects
None; insider sale does not affect biotech sector broadly.
None; limited to US market.
None
Counterpoint
The sale could signal insider confidence if the remaining stake is still sizable.
Key entities
- companyMaze Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
- insiderDandekar Atul
Chief Strategy and Business Officer at Maze Therapeutics.